US20130197087A1 - Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy - Google Patents

Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy Download PDF

Info

Publication number
US20130197087A1
US20130197087A1 US13/819,952 US201113819952A US2013197087A1 US 20130197087 A1 US20130197087 A1 US 20130197087A1 US 201113819952 A US201113819952 A US 201113819952A US 2013197087 A1 US2013197087 A1 US 2013197087A1
Authority
US
United States
Prior art keywords
composition
chemotherapy
epa
dha
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/819,952
Other languages
English (en)
Inventor
Ewald Schlotzer
Barbara Krampitz
Ulrich Suchner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi Deutschland GmbH
Original Assignee
Fresenius Kabi Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43244801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130197087(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Deutschland GmbH filed Critical Fresenius Kabi Deutschland GmbH
Priority to US13/819,952 priority Critical patent/US20130197087A1/en
Assigned to FRESENIUS KABI DEUTSCHLAND GMBH reassignment FRESENIUS KABI DEUTSCHLAND GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SUCHNER, ULRICH, Krampitz, Barbara, SCHLOTZER, EWALD
Publication of US20130197087A1 publication Critical patent/US20130197087A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs

Definitions

  • the present invention relates to the use of an omega-3 fatty acid-comprising composition for administration to cancer patients prior to the start of a cycle of chemotherapy or radiation therapy.
  • the administration of the composition improves the efficacy of the therapy. Adverse effects of the therapy are prevented or attenuated by the administration of the therapy.
  • Cancers are one of the most common causes of death worldwide. In the case of women, the most common cancers are breast cancer, lung cancer and colorectal cancer. Particularly common in men is the development of prostate cancer, lung cancer and colorectal cancer (Jemal et al. 2009; CA Cancer J Clin; 59(4): 225-49). Common to all cancers are changes in the cell leading to uncontrolled growth thereof.
  • the cancer is treated by surgical removal of the tumor, chemotherapy, radiation therapy, immunotherapy or further so-called targeted therapy forms, which for example comprise treatment with monoclonal antibodies.
  • chemotherapy and radiation therapy as the sole therapy.
  • a plurality of therapy forms are often combined. For instance, a tumor is frequently first removed by surgical means and chemotherapy is then applied in order to kill any cancer cells remaining in the body.
  • Radiation therapy can, for example, be used for first achieving shrinkage of the tumor, facilitating the subsequent surgical removal of the tumor.
  • a combination of chemotherapy and radiation therapy (“radiochemotherapy”) is used, inter alia, in the treatment of tumors of the rectum, of the cervix, of the lungs, of the breasts, of the esophagus and in head and neck tumors.
  • the disease is, in a multiplicity of cases, not curable with respect to the cause.
  • the therapy may only slow the progression of the disease (Jemal et al. 2009; CA Cancer J Clin; 59(4): 225-49).
  • chemotherapeutics used for the treatment of cancers and also the frequently used radiation therapy cause strong adverse effects in the patients (Ladewski et al. 2003; J Clin Oncol. 21(20): 3859-66). This can be explained by the fact that the action of chemotherapeutics and radiation therapy is not restricted to the cancer cells. There is damage to healthy cells. Especially affected are those cells which exhibit strong activity with regard to cell division, for example the cells of the mucous membranes. For example stomatitis, mucositis, emesis and diarrhea are observed. Further adverse effects affect the hematopoietic system; even nerve cells may be affected.
  • the strong adverse affects usually associated with a cancer therapy stress the patient and are ultimately also a codeterminant as regards to what extent or in which dose the chemotherapy or radiation therapy can be used.
  • compositions and methods for preventing or weakening the occurrence of adverse effects in cancer therapies This could improve the tolerance, efficacy and acceptance of the therapy by the patients.
  • compositions and methods for increasing the efficacy of chemotherapy or radiation therapy Increased efficacy allows the reduction of the doses to be used for the therapy and, as a result, also a reduction of the adverse effects associated with the therapy.
  • the invention relates to a composition comprising omega-3 fatty acids.
  • the composition can be used to improve the efficacy of a chemotherapy or of a radiation therapy and/or to prevent or reduce adverse effects caused by the chemotherapy or the radiation therapy in a patient who has developed cancer, wherein the composition is to be administered to the patient prior to the start of a cycle of the chemotherapy or of the radiation therapy.
  • FIG. 1 Administration regimen for the administration of a composition comprising EPA and DHA (Omegaven®) prior to the start of a cycle of chemotherapy.
  • the figure shows by way of example the consecutive intravenous administration of Omegaven® two days (“Day 1”) and one day (“Day 2”) prior to the start of a cycle (“Day 3”) of a 5-FU-based adjuvant chemotherapy in a patient with colorectal cancer.
  • the chemotherapy regimen applied is known as the FOLFOX regimen.
  • FOLFOX is a combination therapy consisting of the medicaments folinic acid, fluorouracil and oxaliplatin.
  • FOLFOX is the most common therapy regimen for the treatment of colon cancer.
  • the dose of the medicaments of the chemotherapy is given as mg per m 2 of body surface area of the patient.
  • Omegaven® is administered in a dose of 2 mL per kg of body weight of the patient per day.
  • the representation of the days and of the administered composition and medicaments is diagrammatic and the width of the boxes does not correspond
  • FIG. 2 Administration regimen for the administration of a composition comprising EPA and DHA (Omegaven®) prior to the start of a cycle of chemotherapy, with the administration also additionally taking place 3 hours prior to the start of the cycle.
  • the figure shows by way of example the consecutive intravenous administration of Omegaven® two days (“Day 1”), one day (“Day 2”) and on the day of the start (“Day 3”) of a cycle of a 5-FU-based adjuvant chemotherapy according to the FOLFOX regimen in a patient with colorectal cancer.
  • the administration on the day of the start of the chemotherapy cycle is carried out 3 hours (“ ⁇ 3 h”) prior to the start of the cycle, and is completed no later than one hour (“ ⁇ 1 h”) prior to the start of the cycle.
  • the dose of the medicaments of the chemotherapy is given as mg per m 2 of body surface area of the patient.
  • Omegaven® is administered in a dose of 2 mL per kg of body weight of the patient per day.
  • the representation of the days and of the administered composition and medicaments is diagrammatic and the width of the boxes does not correspond to the duration of administration.
  • FIG. 3 Administration regimen for the administration of a composition comprising EPA and DHA (Omegaven®) prior to the start of each cycle of a chemotherapy comprising 12 cycles.
  • the figure shows by way of example the consecutive intravenous administration of Omegaven® two days and one day prior to each cycle of a 12-cycle-comprising, 5-FU-based adjuvant chemotherapy according to the FOLFOX regimen in a patient with colorectal cancer.
  • the administration is, in each case, carried out prior to the start of a cycle.
  • One cycle of the chemotherapy encompasses two days.
  • the cycle is followed by a multiday treatment break in which the patient does not receive any chemotherapeutics, and which lasts until the start of the next cycle of the chemotherapy. It is followed by the second cycle of the chemotherapy.
  • Omegaven® is administered prior to the second cycle, i.e., during the treatment break.
  • the administration regimen for Omegaven® is carried out in an identical manner for the following cycles 3 to 11 (not shown). Omegaven® is thus administered two days and one day prior to the start of each cycle of the chemotherapy.
  • variations in the administration regimen are also possible in principle, provided the administration is carried out prior to the start of the cycle, and provided the administration does not fall into the cycle preceding the particular cycle.
  • the administration prior to the twelfth (last) cycle of the chemotherapy is carried out as described above for cycles 1 to 11.
  • the representation of the days and of the administered composition and medicaments is diagrammatic and the width of the boxes does not correspond to the duration of administration.
  • FIG. 4 Influence of DHA and EPA on the survival of HT-29 cells following irradiation.
  • the figure shows the survival of HT-29 cells after a two-day pretreatment with from 20 ⁇ M to 100 ⁇ M DHA (A) or EPA (B) followed by irradiation at 0 Gy (white bars), 2 Gy (light-gray bars), 4 Gy (medium-gray bars) or 6 Gy (black bars).
  • the values are reported as mean values (%) ⁇ standard deviation relative to the untreated controls (6 per group). *P ⁇ 0.05 compared to 0 Gy; ⁇ P ⁇ 0.05 compared to untreated control.
  • administration encompasses enteral and parenteral administration.
  • Enteral administration describes the uptake via the intestine, for example by oral intake, or by means of transnasal, gastric or jejunal probes.
  • parenteral administration is understood to mean administration with circumvention of the intestine. It thus encompasses, for example, intravenous injection or infusion and intraarterial injection or infusion.
  • Intraarterial is understood to mean administration into an arterial blood vessel
  • intravenous is understood to mean administration into a venous blood vessel.
  • Injection encompasses administration via a syringe. Generally, it is achieved in the form of a bolus. However, a continuous injection by means of syringe pumps is equally possible.
  • Infusion describes the continuous administration of the composition into a blood vessel, which administration can, for example, be carried out via a peripheral or central venous catheter.
  • Transdermal administration administration via the skin is also encompassed.
  • Chemotherapy is understood to mean the medicamentous therapy of cancer diseases.
  • a chemotherapy can encompass the treatment with one or more medicaments, known as chemotherapeutics, for the therapy of cancers. It is possible to use a combination of medicaments which are administered at the same time or at different times. Chemotherapeutics used for the medicamentous therapy of cancers are sometimes also used for the treatment of other diseases, for example severe autoimmune diseases.
  • FOLFOX is a chemotherapy regimen used for the chemotherapy of colorectal cancer, comprising the medicaments oxaliplatin, folinic acid (leucovorin) and fluorouracil (5-FU).
  • FOLFIRI is likewise a chemotherapy regimen used for the chemotherapy of colorectal cancer, comprising the medicaments folinic acid (leucovorin), fluorouracil (5-FU) and irinotecan.
  • Radiation therapy encompasses the application of ionizing radiation, for example gamma radiation, X-radiation and electrons. It also encompasses the application of neutrons, protons and heavy ions for the treatment of cancer patients. Radiation therapy can, for example, be carried out in the form of teletherapy or brachytherapy. In the context of the present invention, the expression “administration of irradiation” or “administration of the irradiation” can be used equivalently to the expression “irradiate”.
  • a cycle is understood to mean a period in which irradiation, a chemotherapeutic, multiple chemotherapeutics or a combination thereof are administered to a patient.
  • the cycle encompasses the period from the start of the one-off administration to the end of the one-off administration.
  • the cycle encompasses the period from the start of the first administration to the end of the last administration.
  • the administration of the irradiation, of the chemotherapeutic, of the chemotherapeutics or of a combination thereof can be carried out at the same time or at different times and can be repeated individually or in combination. If the patient does not receive irradiation or a chemotherapeutic or multiple chemotherapeutics on a day following administration of irradiation, of a chemotherapeutic, of chemotherapeutics or of a combination thereof, the cycle is finished with the end of the last administration.
  • the cycle is followed by a treatment break. This is characterized in that no irradiation and no chemotherapy are administered to the patient during the treatment break.
  • a treatment break can be followed by one or more further cycles.
  • a chemotherapy or radiation therapy can thus comprise one or more cycles.
  • the start of the first cycle of a chemotherapy or of a radiation therapy can be the time from which a patient receives a particular chemotherapy or a particular radiation therapy for the first time, i.e., the time from which irradiation, a chemotherapeutic, multiple chemotherapeutics or a combination are administered to the patient for the first time.
  • the start of a cycle is the time at which the administration of irradiation, of a chemotherapeutic, of multiple chemotherapeutics or a combination thereof starts.
  • the cycle starts with the start of the administration of the element which is administered first of all, and ends with the end of the administration of the element which is administered last.
  • solid tumors encompass tumors which are not derived from the hematopoietic system.
  • Solid tumors are hard, initially localized tumors. The term also encompasses spreading of the tumor to other organs, known as metastases.
  • Solid tumors can be benign or malignant. If a malignant solid tumor appears in a patient, the patient has developed cancer. All types of solid tumors are encompassed.
  • Preferred solid tumors are colorectal cancer, breast cancer, pancreatic cancer, liver cancer, lung cancer, and stomach cancer. Very particular preference is given to colorectal cancer.
  • nonsolid tumors encompasses cancer types of the hematopoietic system.
  • the term also encompasses spreading to other organs, known as metastases.
  • the nonsolid tumors include leukemias, comprising acute myeloid leukemia (AML, also referred to as acute nonlymphocytic leukemia (ANLL)), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and lymphomas, comprising Hodgkin lymphoma and non-Hodgkin lymphoma.
  • AML acute myeloid leukemia
  • CML chronic myelogenous leukemia
  • ALL acute lymphoblastic leukemia
  • CLL chronic lymphocytic leukemia
  • lymphomas comprising Hodgkin lymphoma and non-Hodgkin lymphoma.
  • colorectal cancer encompasses cancers of the colon and/or of the rectum. Spreading of the colorectal cancer to other organs, known as metastases, is also encompassed.
  • improvement in efficacy is understood to mean an increase in the efficacy of a chemotherapy or radiation therapy.
  • the chemotherapy or radiation therapy exerts at the same dose a stronger effect on the tumor. This can lead to parameters such as tumor growth, tumor volume, or tumor cell metastasis, or a combination thereof, being favorably influenced.
  • An improvement in the efficacy of a chemotherapy or radiation therapy can, for example, lead to an intensified reduction in tumor volume.
  • An improvement in efficacy can also lead to the tumor volume remaining constant over a prolonged time, or the tumor growing less rapidly or less strongly than would be the case without the improvement in efficacy.
  • An increase in the efficacy of a chemotherapy or radiation therapy can result in being able to select a lower dose of the therapy and, nevertheless, being able to achieve the same effect on the tumor as that provided by the higher dose with no improvement in its efficacy.
  • Increased efficacy can be caused by increased chemosensitivity of the cells.
  • chemosensitivity describes the sensitivity of cancer cells to growth-inhibiting cytostatics.
  • the chemosensitivity of cancer cells is a frequent codeterminant with regard to the success of the chemotherapy.
  • prevention of adverse effects is understood to mean prevention of the occurrence of one or more adverse effects typically associated with a treatment.
  • the reduction of adverse effects is understood to mean the attenuation of the adverse effects, i.e., a less strongly pronounced occurrence or a temporally reduced occurrence of the adverse effect.
  • a person skilled in the art is aware of the adverse effects which may be associated with a treatment and their manifestations.
  • Adverse effects are effects which occur in addition to the intended actual effect of a medicament or of a treatment form. Adverse effects are also referred to as undesired drug effects.
  • the adverse effects of chemotherapy for treating cancer patients include, inter alia: gastrointestinal adverse effects (for example, dry mouth, inflammation in the mouth, inflammatory changes in the mucous membrane (mucositis) in the gastrointestinal tract, diarrhea), hematologic adverse effects (for example, anemia, thrombopenia, neutropenia, leukopenia, myelosuppression, disruption of the endogenous immune system, disruption of blood coagulation), reduction in liver weight, neurotoxic adverse effects (for example, nerve damage, disruption of touch sensitivity or esthesia), adverse effects affecting the heart such as, for example, cardiac muscle diseases (cardiomyopathy), inflammatory adverse effects, weight loss, limited function of the immune system, hair loss, fatigue, nausea, emesis, or a combination thereof.
  • gastrointestinal adverse effects for example, dry mouth, inflammation in the mouth, inflammatory changes in the mucous membrane (mucositis) in the gastrointestinal tract, diarrhea
  • hematologic adverse effects for example, anemia, thrombopenia, neutropenia, le
  • the adverse effects observed in the case of radiation therapy include, inter alia: fatigue; loss of appetite, exhaustion, headaches, nausea, emesis, diarrhea, damage to the oral and pharyngeal mucous membrane, damage to the mucous membrane of the digestive tract, damage to the bladder.
  • Omega-3 fatty acids are polyunsaturated fatty acids in which the last double bond of the fatty acid is in the omega-3 position, i.e., in the third from last C—C bond seen from the carboxyl end.
  • the omega-3 fatty acids contained in the composition according to the invention can be of plant or animal origin, for example the fatty acids can be obtained from algae or from fish. Preference is given to long-chain and very long-chain omega-3 fatty acids. Particular preference is given to omega-3 fatty acids selected from the group consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a combination thereof.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • VLCFAs Very long-chain omega-3 fatty acids
  • Examples of VLCFAs are linolenic acid, eicosapentaenoic acid and docosahexaenoic acid.
  • Eicosapentaenoic acid or (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoic acid is a polyunsaturated fatty acid from the class of omega-3 fatty acids having the molecular formula C 20 H 30 O 2 .
  • Docosahexaenoic acid (DHA) or (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid is a polyunsaturated fatty acid from the class of omega-3 fatty acids having the molecular formula C 22 H 32 O 2 .
  • Fish oil is understood to mean oil which is obtained from fish and which contains omega-3 fatty acids.
  • the fish oil can be obtained from sea fishes, for example from deep-sea fishes.
  • Fish oil suitable for parenteral administration in humans is referred to as highly purified fish oil.
  • MCTs Medium-chain triglycerides
  • MCTs are triglycerides which comprise fatty acid radicals of medium length (a length of from 6 to 12 C atoms).
  • Examples of MCTs are caproic acid (C6), caprylic acid (C8), capric acid (C10), and lauric acid (C12), or a combination thereof.
  • iron is understood to mean an iron salt suitable for parenteral administration.
  • high-molecular-weight iron compounds consisting of a polymeric iron(III) oxide-hydroxide core associated with a carbohydrate shell are also encompassed. Examples are iron citrate, iron dextran, iron sulfate, ferric carboxymaltose, iron(II) chloride, iron hydrogen aspartate, iron(II) iodide, iron oxide, iron(III) phosphate, iron(III) sodium gluconate complex, iron sucrose complex and iron saccharate complex.
  • Consecutive administration is understood to mean the administration on two or more successive days.
  • the consecutive administration can, for example, be carried out on 2, 3, or 4 successive days.
  • 24 hours, or else more than or less than 24 hours can lie between two successive administrations.
  • 0 to 48 hours can lie between two successive administrations, for example 5 to 42 hours, 10 to 38 hours or 12 to 36 hours.
  • the administration can be carried out on one day in the morning, but on the following day at midday or in the evening.
  • 20 to 28 hours, particularly preferably 22 to 26, more preferably 24 hours lie between two successive administrations.
  • the administration can equally be carried out on one day in the evening and on the following day in the morning or at midday.
  • a consecutive administration on two or more successive days does not rule out a repeated administration on the same day.
  • the composition can be administered once, twice, three times, four times or five times per day.
  • the present invention is based on the finding that an omega-3 fatty acid-comprising composition can be used to improve the efficacy of a chemotherapy or of a radiation therapy in a patient who has developed cancer.
  • the composition can equally be used to prevent or reduce adverse effects caused by the chemotherapy or the radiation therapy in a patient who has developed cancer.
  • the composition comprises at least one omega-3 fatty acid.
  • the fatty acids can be EPA, DHA or a combination thereof.
  • the composition can contain further omega-3 fatty acids.
  • a composition comprising long-chain or very long-chain omega-3 fatty acids is likewise preferred.
  • the composition can comprise one or more different omega-3 fatty acids. If “omega-3 fatty acids” is mentioned in the plural, one or more omega-3 fatty acids may be comprised, unless otherwise defined. If “omega-3 fatty acids” is mentioned in the singular, one or more omega-3 fatty acids may be comprised, unless otherwise defined.
  • composition can comprise further preferred additives, such as MCTs, iron, or a combination thereof.
  • the composition can be an emulsion.
  • composition can be administered enterally or parenterally, preferably parenterally and most preferably intravenously.
  • the efficacy of the chemotherapy or radiation therapy is improved when a composition comprising omega-3 fatty acids such as EPA and DHA is administered prior to the start of a cycle of the therapy.
  • An additional administration during the cycle of the therapy or after completion of the cycle is likewise possible.
  • the efficacy of the chemotherapy or radiation therapy is particularly improved when the composition is administered parenterally. The improvement in efficacy affects cancer cells.
  • compositions prior to the start of a cycle of the therapy also leads to the prevention or reduction of adverse effects caused by the chemotherapy or the radiation therapy.
  • a particularly effective prevention or reduction of adverse effects caused by the chemotherapy or the radiation therapy is achieved with parenteral administration of the composition according to the invention.
  • omega-3 fatty acids can be incorporated more effectively into the cell membranes as a result of the administration thereof prior to the start of a cycle of a chemotherapy or radiation therapy, especially as a result of the parenteral administration thereof, for example intravenous administration.
  • omega-3 fatty acids preferably EPA and/or DHA
  • omega-3 fatty acids are then already present in the cell membrane of healthy cells, where they can counteract the toxicity of the chemotherapeutics or the irradiation and thus prevent or reduce the adverse effects thereof. Weakening of the effect of the chemotherapeutic or of the radiation therapy on the tumor cell is not observed.
  • the protective effect of the composition affects the healthy cells.
  • omega-3 fatty acids such as EPA and/or DHA from the composition are advantageously already provided in the body and incorporation into cell membranes has already taken place.
  • omega-3 fatty acids such as EPA and/or DHA
  • EPA and/or DHA Owing to the parenteral administration, a high dose of omega-3 fatty acids such as EPA and/or DHA can be advantageously administered.
  • the omega-3 fatty acids Owing to the intravenous administration, the omega-3 fatty acids are provided rapidly for incorporation into the cell membrane; there are no losses in intestinal absorption.
  • the composition according to the invention therefore develops especially rapidly its efficacy in terms of the prevention or reduction of adverse effects and the improvement of the efficacy of a chemotherapy or radiation therapy, and even in small amounts.
  • composition Even if the composition is only administered just prior to the start of a cycle of the chemotherapy or of the radiation therapy, for example if the composition is administered 48 hours or 24 hours prior to the start of a cycle or even if the composition is administered three hours prior to the start of a cycle, the rapid and direct provision ensures the complete efficacy of the composition. There is no need for prolonged supplementation over several weeks. However, consecutive administration on two or more successive days can intensify the incorporation of omega-3 fatty acids, such as DHA and EPA, into the cell membranes.
  • the composition can, in addition to the administration prior to the start of a cycle, also be administered during and/or after a cycle.
  • omega-3 fatty acids such as EPA and DHA
  • EPA and DHA are already present prior to the start of a cycle of a chemotherapy or of a radiation therapy, in contrast to compositions known from the prior art, which have to be administered at the start or after the start of a chemotherapy or radiation therapy.
  • the invention provides a composition which contains omega-3 fatty acids, such as EPA and/or DHA, and is used for use in the improvement of the efficacy of a chemotherapy or of a radiation therapy and/or in the prevention or reduction of adverse effects caused by the chemotherapy or the radiation therapy in a patient who has developed cancer.
  • omega-3 fatty acids such as EPA and/or DHA
  • composition according to the invention is administered to the patient prior to the start of a cycle of the chemotherapy or of the radiation therapy.
  • composition can, in addition to the administration prior to the start of a cycle, also be effected during the cycle or after the cycle.
  • the administration can be carried out continuously or intermittently.
  • the administration can be carried out parenterally.
  • the parenteral administration is preferably carried out intravenously.
  • the intravenous administration can be carried out as a continuous infusion or as a bolus administration.
  • the composition can be administered such that an intravenous administration amounts to or does not exceed from 0.05 mL to 5.0 mL per kg of body weight per hour.
  • the intravenous administration can, for example, amount to or not exceed from 0.1 mL to 5.0 mL, from 0.5 mL to 5.0 mL, from 1.0 mL to 5.0 mL, from 1.5 mL to 5.0 mL, from 2.0 mL to 5.0 mL, from 2.5 mL to 5.0 mL, from 3.0 mL to 5.0 mL, from 3.5 mL to 5.0 mL, from 4.0 mL to 5.0 mL or from 4.5 mL to 5.0 mL per kg of body weight per hour.
  • the intravenous administration can amount to or not exceed from 5.0 mL to 0.05 mL, from 4.5 mL to 0.05 mL, from 4.0 mL to 0.05 mL, from 3.5 mL to 0.05 mL, from 3.0 mL to 0.05 mL, from 2.5 mL to 0.05 mL, from 2.0 mL to 0.05 mL, from 1.5 mL to 0.05 mL, from 1.0 mL to 0.05 mL or from 0.5 mL to 0.05 mL per kg of body weight per hour.
  • the intravenous administration is carried out such that the administration amounts to or does not exceed from 0.5 mL to 3.5 mL per kg of body weight per hour, preferably from 1.0 mL to 3.0 mL, from 1.5 mL to 2.5 mL, most preferably 2.0 mL per kg of body weight per hour.
  • an intravenous administration which amounts to or does not exceed from 0.3 to 0.5 mL per kg of body weight per hour.
  • composition according to the invention can be administered to the patient prior to the start of the first cycle of the chemotherapy or of the radiation therapy.
  • the composition according to the invention is administered prior to multiple cycles, in each case prior to the start of a cycle of the chemotherapy or of the radiation therapy. Particular preference is given to administering the composition prior to each of the cycles.
  • composition according to the invention to improve the efficacy of a chemotherapy or of a radiation therapy and/or to prevent or reduce adverse effects caused by the chemotherapy or the radiation therapy is, in principle, not restricted to particular adverse effects.
  • composition according to the invention is used to improve the efficacy of a chemotherapy or of a radiation therapy and/or to prevent or reduce adverse effects caused by the chemotherapy or the radiation therapy, the adverse effects being preferably selected from the group consisting of gastrointestinal adverse effects, hematologic adverse effects, reduction in liver weight, neurotoxic adverse effects, adverse effects affecting the heart, inflammatory adverse effects, weight loss, limited function of the immune system, reduction of inflammations or a combination thereof.
  • composition according to the invention for preventing or reducing adverse effects which occur in the case of the chemotherapy or radiation therapy of a colorectal cancer.
  • composition according to the invention for use in the improvement of the efficacy of a chemotherapy or of a radiation therapy and/or in the prevention or reduction of adverse effects caused by the chemotherapy or the radiation therapy in a patient who has developed cancer is, in principle, not restricted to particular cancers.
  • the composition can be administered to solid or nonsolid tumors.
  • Preferred solid tumors are selected from the group consisting of colorectal cancer, breast cancer, pancreatic cancer, liver cancer, lung cancer, and stomach cancer. Very particular preference is given to the composition for use in a patient who has developed colorectal cancer.
  • composition according to the invention can be administered in the case of any form of chemotherapy.
  • chemotherapeutic selected from the group consisting of 5-fluorouracil, gemcitabine, doxorubicin, paclitaxel, mitomycin, cyclophosphamide, epirubicin, arabinosylcytosine, tamoxifen, irinotecan, oxaliplatin, folinic acid, cisplatin, taxanes, vinca alkaloids, epipodophyllotoxins, synthetic alkaloids, cytarabine, nitrosourea, dacarbazine, fludarabine, ifosfamide, mitomycin C, tamoxifen or a combination thereof.
  • the chemotherapy can also encompass chemotherapeutics other than and/or further to the aforementioned ones.
  • composition can also be used when the patient receives further medicaments and/or enteral or parenteral nutrition in addition to the chemotherapy or the radiation therapy.
  • the composition according to the invention is administered for use in the improvement of the efficacy of a chemotherapy or of a radiation therapy and/or in the prevention or reduction of adverse effects caused by the chemotherapy or the radiation therapy in the case of a chemotherapy comprising 5-fluorouracil (5-FU), the chemotherapy preferably being FOLFOX or FOLFIRI.
  • a chemotherapy comprising 5-fluorouracil (5-FU)
  • the chemotherapy preferably being FOLFOX or FOLFIRI.
  • the radiation therapy can be selected from the group consisting of teletherapy and brachytherapy.
  • composition according to the invention can also be used when the patient receives chemotherapy and radiation therapy. If the cycle of the chemotherapy and of the radiation therapy does not start at the same time, the composition according to the invention is preferably to be administered prior to the one of the two cycles which starts at the earlier time.
  • the composition according to the invention can comprise from 0.5 g/100 mL to 10.0 g/100 mL EPA.
  • the composition can comprise from 1 g/100 mL to 10.0 g/100 mL EPA, from 1.5 g/100 mL to 10.0 g/100 mL EPA, from 2 g/100 mL to 10.0 g/100 mL EPA, from 2.5 g/100 mL to 10.0 g/100 mL EPA, from 3 g/100 mL to 10.0 g/100 mL EPA, from 3.5 g/100 mL to 10.0 g/100 mL EPA, from 4 g/100 mL to 10.0 g/100 mL EPA, from 4.5 g/100 mL to 10.0 g/100 mL EPA, from 5 g/100 mL to 10.0 g/100 mL EPA, from 5.5 g/100 mL to 10.0 g/100
  • the composition can comprise from 0.5 g/100 mL to 9.5 g/100 mL EPA, from 0.5 g/100 mL to 9 g/100 mL EPA, from 0.5 g/100 mL to 8.5 g/100 mL EPA, from 0.5 g/100 mL to 8 g/100 mL EPA, from 0.5 g/100 mL to 7.5 g/100 mL EPA, from 0.5 g/100 mL to 7 g/100 mL EPA, from 0.5 g/100 mL to 6.5 g/100 mL EPA, from 0.5 g/100 mL to 6 g/100 mL EPA, from 0.5 g/100 mL to 5.5 g/100 mL EPA, from 0.5 g/100 mL to 5 g/100 mL EPA, from 0.5 g/100 mL to 4.5 g/100 mL EPA, from
  • the composition comprises from 1.0 g/100 mL to 7.0 g/100 mL EPA.
  • a composition comprising from 1.0 g/100 mL to 4.0 g/100 mL EPA.
  • the composition can comprise from 0.5 g/100 mL to 10.0 g/100 mL DHA.
  • the composition can comprise from 1 g/100 mL to 10.0 g/100 mL DHA, from 1.5 g/100 mL to 10.0 g/100 mL DHA, from 2 g/100 mL to 10.0 g/100 mL DHA, from 2.5 g/100 mL to 10.0 g/100 mL DHA, from 3 g/100 mL to 10.0 g/100 mL DHA, from 3.5 g/100 mL to 10.0 g/100 mL DHA, from 4 g/100 mL to 10.0 g/100 mL DHA, from 4.5 g/100 mL to 10.0 g/100 mL DHA, from 5 g/100 mL to 10.0 g/100 mL DHA, from 5.5 g/100 mL to 10.0 g/100 mL D
  • the composition can comprise from 0.5 g/100 mL to 9.5 g/100 mL DHA, from 0.5 g/100 mL to 9 g/100 mL DHA, from 0.5 g/100 mL to 8.5 g/100 mL DHA, from 0.5 g/100 mL to 8 g/100 mL DHA, from 0.5 g/100 mL to 7.5 g/100 mL DHA, from 0.5 g/100 mL to 7 g/100 mL DHA, from 0.5 g/100 mL to 6.5 g/100 mL DHA, from 0.5 g/100 mL to 6 g/100 mL DHA, from 0.5 g/100 mL to 5.5 g/100 mL DHA, from 0.5 g/100 mL to 5 g/100 mL DHA, from 0.5 g/100 mL to 4.5 g/100 mL DHA, from
  • the composition comprises from 1.0 g/100 mL to 7.0 g/100 mL DHA.
  • a composition containing from 1.0 g/100 mL to 4.0 g/100 mL DHA is particularly preferred.
  • the composition according to the invention can comprise from 5 g/100 mL to 50 g/100 mL highly purified fish oil.
  • the composition can comprise from 10 g/100 mL to 50 g/100 mL highly purified fish oil, from 15 g/100 mL to 50 g/100 mL highly purified fish oil, from 20 g/100 mL to 50 g/100 mL highly purified fish oil, from 25 g/100 mL to 50 g/100 mL highly purified fish oil, from 30 g/100 mL to 50 g/100 mL highly purified fish oil, from 35 g/100 mL to 50 g/100 mL highly purified fish oil, from 40 g/100 mL to 50 g/100 mL highly purified fish oil, or from 45 g/100 mL to 50 g/100 mL highly purified fish oil.
  • the composition can comprise from 5 g/100 mL to 45 g/100 mL highly purified fish oil, from 5 g/100 mL to 40 g/100 mL highly purified fish oil, from 5 g/100 mL to 35 g/100 mL highly purified fish oil, from 5 g/100 mL to 30 g/100 mL highly purified fish oil, from 5 g/100 mL to 25 g/100 mL highly purified fish oil, from 5 g/100 mL to 20 g/100 mL highly purified fish oil, from 5 g/100 mL to 15 g/100 mL highly purified fish oil, or from 5 g/100 mL to 10 g/100 mL highly purified fish oil.
  • Preference is given to a composition comprising from 10 g/100 mL to 40 g/100 mL highly purified fish oil, for example from 15 g/100 mL to 35 g/100 mL highly
  • the composition can comprise EPA, DHA or a combination thereof.
  • the composition can also contain further additives.
  • the composition according to the invention contains further additives selected from medium-chain fatty acids (MCTs) or iron, or a combination thereof.
  • MCTs medium-chain fatty acids
  • iron iron
  • the addition of MCTs and/or iron to the composition leads to a synergistic effect with the omega-3 fatty acids contained in the composition according to the invention, which effect further improves the efficacy of the composition.
  • composition according to the invention can comprise from 5 g/100 mL to 50 g/100 mL MCTs.
  • the composition can comprise 10 g/100 mL-50 g/100 mL MCTs, 15 g/100 mL-50 g/100 mL MCTs, 20 g/100 mL-50 g/100 mL MCTs, 25 g/100 mL-50 g/100 mL MCTs, 30 g/100 mL-50 g/100 mL MCTs, 35 g/100 mL-50 g/100 mL MCTs, 40 g/100 mL-50 g/100 mL MCTs, or 45 g/100 mL-50 g/100 mL MCTs.
  • the composition can comprise 5 g/100 mL-45 g/100 mL MCTs, 5 g/100 mL-40 g/100 mL MCTs, 5 g/100 mL-35 g/100 mL MCTs, 5 g/100 mL-30 g/100 mL MCTs, 5 g/100 mL-25 g/100 mL MCTs, 5 g/100 mL-20 g/100 mL MCTs, 5 g/100 mL-15 g/100 mL MCTs, or 5 g/100 mL-10 g/100 mL MCTs.
  • Preference is given to a composition comprising 10 g/100 mL-40 g/100 mL MCTs, for example 15 g/100 mL-35 g/100 mL MCTs.
  • the composition according to the invention can comprise 0.1 mg/100 mL-0.5 mg/100 mL iron.
  • the composition can comprise 0.15 mg/100 mL-0.5 mg/100 mL iron, 0.2 mg/100 mL-0.5 mg/100 mL iron, 0.25 mg/100 mL-0.5 mg/100 mL iron, 0.3 mg/100 mL-0.5 mg/100 mL iron, 0.35 mg/100 mL-0.5 mg/100 mL iron, 0.4 mg/100 mL-0.5 mg/100 mL iron or 0.45 mg/100 mL-0.5 mg/100 mL iron.
  • the composition can comprise 0.1 mg/100 mL-0.45 mg/100 mL iron, 0.1 mg/100 mL-0.4 mg/100 mL iron, 0.1 mg/100 mL-0.35 mg/100 mL iron, 0.1 mg/100 mL-0.3 mg/100 mL iron, 0.1 mg/100 mL-0.25 mg/100 mL iron, 0.1 mg/100 mL-0.2 mg/100 mL iron, 0.1 mg/100 mL-0.15 mg/100 mL iron.
  • Preference is given to a composition comprising 0.15 mg/100 mL-0.45 mg/100 mL iron, for example 0.2 mg/100 mL-0.4 mg/100 mL iron.
  • the composition is administered prior to the start of a cycle of a chemotherapy or radiation therapy.
  • the composition can be administered from 96 hours to 24 hours prior to the start of a cycle, preferably from 72 to 24 hours prior to the start of a cycle. Very particular preference is given to the composition being administered from 48 to 24 hours prior to the start of a cycle of the chemotherapy or of the radiation therapy.
  • the composition can also additionally be administered between 24 hours and 1 hour prior to the start of the cycle.
  • administration between 10 and 2 hours prior to the start of the cycle is advantageous; very particular preference is given to administration 3 hours prior to the start of a cycle.
  • composition according to the invention can, in principle, be administered once or repeatedly prior to the start of a cycle of a chemotherapy or radiation therapy.
  • the composition can, for example, be administered twice, three times, four times, or five times.
  • the composition can be administered consecutively.
  • a chemotherapy or radiation therapy comprises multiple cycles.
  • the composition can be administered prior to the start of one cycle or prior to multiple cycles, in each case prior to the start of the cycle.
  • the composition can be administered prior to each of the cycles.
  • composition can be administered consecutively on multiple successive days, the composition preferably being administered on three successive days.
  • composition can be administered parenterally, preferably intravenously.
  • composition it is possible to administer from 5 mg to 250 mg, for example from 10 mg to 250 mg, of EPA per kilogram of body weight per day.
  • from 25 mg to 250 mg of EPA from 50 mg to 250 mg of EPA, from 75 mg to 250 mg of EPA, from 100 mg to 250 mg of EPA, from 125 mg to 250 mg of EPA, from 150 mg to 250 mg of EPA, from 175 mg to 250 mg of EPA, from 200 mg to 250 mg of EPA, from 225 mg to 250 mg of EPA per kilogram of body weight per day may be administered.
  • composition preference is given to administering from 5 mg to 100 mg of EPA, for example from 15 mg to 85 mg of EPA, from 20 mg to 80 mg of EPA, from 25 mg to 75 mg of EPA, from 30 mg to 70 mg of EPA, from 35 mg to 65 mg of EPA, or from 40 mg to 60 mg of EPA, per kilogram of body weight per day.
  • very particular preference is given to administration of from 45 mg to 55 mg of EPA, 45 mg of EPA, 46 mg of EPA, 47 mg of EPA, 48 mg of EPA, 49 mg of EPA, 50 mg of EPA, 51 mg of EPA, 52 mg of EPA, 53 mg of EPA, 54 mg of EPA, or 55 mg of EPA per kilogram of body weight per day.
  • composition it is possible to administer from 5 mg to 250 mg, for example from 10 mg to 250 mg, of DHA per kilogram of body weight per day.
  • from 25 mg to 250 mg of DHA from 50 mg to 250 mg of DHA, from 75 mg to 250 mg of DHA, from 100 mg to 250 mg of DHA, from 125 mg to 250 mg of DHA, from 150 mg to 250 mg of DHA, from 175 mg to 250 mg of DHA, from 200 mg to 250 mg of DHA, from 225 mg to 250 mg of DHA per kilogram of body weight per day may be administered.
  • DHA dihydroxyacetylcholine
  • 5 mg to 10 mg of DHA from 5 mg to 25 mg of DHA, from 5 mg to 50 mg of DHA, from 5 mg to 75 mg of DHA, from 5 mg to 100 mg of DHA, from 5 mg to 125 mg of DHA, from 5 mg to 150 mg of DHA, from 5 mg to 175 mg of DHA, from 5 mg to 200 mg of DHA or from 5 mg to 225 mg of DHA per kilogram of body weight per day.
  • DHA preference is given to administering from 5 mg to 100 mg of DHA, for example from 15 mg to 85 mg of DHA, from 20 mg to 80 mg of DHA, from 25 mg to 75 mg of DHA, from 30 mg to 70 mg of DHA, from 35 mg to 65 mg of DHA, or from 40 mg to 60 mg of DHA, per kilogram of body weight per day.
  • composition it is possible to administer from 0.025 g to 1.25 g of fish oil per kilogram of body weight per day.
  • 1.0 g to 0.025 g of fish oil from 1.0 g to 0.025 g of fish oil, from 0.9 g to 0.025 g of fish oil, from 0.8 g to 0.025 g of fish oil, from 0.7 g to 0.025 g of fish oil, from 0.6 g to 0.025 g of fish oil, from 0.5 g to 0.025 g of fish oil, from 0.4 g to 0.025 g of fish oil, from 0.3 g to 0.025 g of fish oil, from 0.3 g to 0.025 g of fish oil, from 0.2 g to 0.025 g of fish oil, from 0.1 g to 0.025 g of fish oil, from 0.075 g to 0.025 g of fish oil or from 0.05 g to 0.025 g of fish oil per kilogram of body weight per day.
  • the fish oil can be highly purified.
  • Omegaven® (Fresenius Kabi) as the composition according to the invention.
  • Omegaven® can be administered in a dose of from 0.25 mL to 12.5 mL per kg of body weight per day.
  • composition it is possible to administer from 0.07 g to 0.7 g of MCTs per kilogram of body weight per day. It is possible to administer from 0.1 g to 0.7 g of MCTs, from 0.2 g to 0.7 g of MCTs, from 0.25 g to 0.7 g of MCTs, from 0.3 g to 0.7 g of MCTs, from 0.35 g to 0.7 g of MCTs, from 0.4 g to 0.7 g of MCTs, from 0.45 g to 0.7 g of MCTs, from 0.5 g to 0.7 g of MCTs, from 0.55 g to 0.7 g of MCTs, from 0.6 g to 0.7 g of MCTs or from 0.65 g to 0.7 g of MCTs per kilogram of body weight per day.
  • composition it is possible to administer from 0.65 g to 0.07 g of MCTs, from 0.6 g to 0.07 g of MCTs, from 0.55 g to 0.07 g of MCTs, from 0.5 g to 0.07 g of MCTs, from 0.45 g to 0.07 g of MCTs, from 0.4 g to 0.07 g of MCTs, from 0.35 g to 0.07 g of MCTs, from 0.3 g to 0.07 g of MCTs, from 0.25 g to 0.07 g of MCTs, from 0.2 g to 0.07 g of MCTs, from 0.15 g to 0.07 g of MCTs or from 0.1 g to 0.07 g of MCTs per kilogram of body weight per day.
  • the composition it is possible to administer from 1 mg to 11 mg of iron per day. It is possible to administer 1 mg-10 mg of iron, 1 mg-9 mg of iron, 1 mg-8 mg of iron, 1 mg-7 mg of iron, 1 mg-6 mg of iron, 1 mg-5 mg of iron, 1 mg-4 mg of iron, 1 mg-3 mg of iron, 1 mg-2 mg of iron per day. It is possible to administer 2 mg-11 mg of iron, 3 mg-11 mg of iron, 4 mg-11 mg of iron, 5 mg-11 mg of iron, 6 mg-11 mg of iron, 7 mg-11 mg of iron, 8 mg-11 mg of iron, 9 mg-11 mg of iron, or 10 mg-11 mg of iron per day. Preference is given to administration of 3 mg-9 mg of iron per day.
  • a composition having a volume of 100 mL and comprising omega-3 fatty acids is provided.
  • the composition can comprise one or more different omega-3 fatty acids.
  • the composition comprises omega-3 fatty acids selected from the group consisting of EPA, DHA, long-chain and very long-chain omega-3 fatty acids or a combination thereof.
  • Particular preference is given to a composition having a volume of 100 mL and comprising from 0.5 g to 10 g of EPA and/or from 0.5 g to 10 g of DHA.
  • the composition can comprise fish oil, for example from 5 g/100 mL to 50 g/100 mL.
  • the provided composition can further comprise MCTs and/or iron.
  • the composition can comprise from 5 g/100 mL to 50 g/100 mL MCTs and/or 0.1 mg/100 mL-0.5 mg/100 mL iron.
  • the provided composition according to the invention having a volume of 100 mL can comprise from 0.5 g to 10.0 g of EPA.
  • the composition can comprise from 1 g to 10.0 g of EPA, from 1.5 g to 10.0 g of EPA, from 2 g to 10.0 g of EPA, from 2.5 g to 10.0 g of EPA, from 3 g to 10.0 g of EPA, from 3.5 g to 10.0 g of EPA, from 4 g to 10.0 g of EPA, from 4.5 g to 10.0 g of EPA, from 5 g to 10.0 g of EPA, from 5.5 g to 10.0 g of EPA, from 6 g to 10.0 g of EPA, from 6.5 g to 10.0 g of EPA, from 7 g to 10.0 g of EPA, from 7.5 g to 10.0 g of EPA, from 8 g to 10.0 g of EPA, from 8.5 g to 10.0 g of EPA, from 9
  • the composition can comprise from 0.5 g to 9.5 g of EPA, from 0.5 g to 9 g of EPA, from 0.5 g to 8.5 g of EPA, from 0.5 g to 8 g of EPA, from 0.5 g to 7.5 g of EPA, from 0.5 g to 7 g of EPA, from 0.5 g to 6.5 g of EPA, from 0.5 g to 6 g of EPA, from 0.5 g to 5.5 g of EPA, from 0.5 g to 5 g of EPA, from 0.5 g to 4.5 g of EPA, from 0.5 g to 4 g of EPA, from 0.5 g to 3.5 g of EPA, from 0.5 g to 3 g of EPA, from 0.5 g to 2.5 g of EPA, from 0.5 g to 2 g of EPA, from 0.5 g to 1.5 g of EPA or from 0.5 g to 1.0 g of EPA.
  • the composition comprises from 1.0 g to 7.0 g of EPA.
  • Very particular preference is given to a composition comprising from 1.0 g to 4.0 g of EPA.
  • the provided composition according to the invention having a volume of 100 mL can comprise from 0.5 g to 10.0 g of DHA.
  • the composition can comprise from 1 g to 10.0 g of DHA, from 1.5 g to 10.0 g of DHA, from 2 g to 10.0 g of DHA, from 2.5 g to 10.0 g of DHA, from 3 g to 10.0 g of DHA, from 3.5 g to 10.0 g of DHA, from 4 g to 10.0 g of DHA, from 4.5 g to 10.0 g of DHA, from 5 g to 10.0 g of DHA, from 5.5 g to 10.0 g of DHA, from 6 g to 10.0 g of DHA, from 6.5 g to 10.0 g of DHA, from 7 g to 10.0 g of DHA, from 7.5 g to 10.0 g of DHA, from 8 g to 10.0 g of DHA, from 8.5 g to 10.0 g of DHA, from 9
  • the provided composition according to the invention having a volume of 100 mL can comprise from 0.5 g to 9.5 g of DHA, from 0.5 g to 9 g of DHA, from 0.5 g to 8.5 g of DHA, from 0.5 g to 8 g of DHA, from 0.5 g to 7.5 g of DHA, from 0.5 g to 7 g of DHA, from 0.5 g to 6.5 g of DHA, from 0.5 g to 6 g of DHA, from 0.5 g to 5.5 g of DHA, from 0.5 g to 5 g of DHA, from 0.5 g to 4.5 g of DHA, from 0.5 g to 4 g of DHA, from 0.5 g to 3.5 g of DHA, from 0.5 g to 3 g of DHA, from 0.5 g to 2.5 g of DHA, from 0.5 g to 2 g of DHA, from 0.5 g to 1.5 g of DHA or from 0.5 g to 1.0
  • the composition comprises from 1.0 g to 7.0 g of DHA.
  • Very particular preference is given to a composition comprising from 1.0 g to 4.0 g of DHA.
  • the provided composition according to the invention having a volume of 100 mL can comprise 5 g-50 g of highly purified fish oil.
  • the composition can comprise 10 g-50 g of highly purified fish oil, 15 g-50 g of highly purified fish oil, 20 g-50 g of highly purified fish oil, 25 g-50 g of highly purified fish oil, 30 g-50 g of highly purified fish oil, 35 g-50 g of highly purified fish oil, 40 g-50 g of highly purified fish oil, or 45 g-50 g of highly purified fish oil.
  • the composition can comprise 5 g-45 g of highly purified fish oil, 5 g-40 g of highly purified fish oil, 5 g-35 g of highly purified fish oil, 5 g-30 g of highly purified fish oil, 5 g-25 g of highly purified fish oil, 5 g-20 g of highly purified fish oil, 5 g-15 g of highly purified fish oil, or 5 g-10 g of highly purified fish oil.
  • the composition can comprise EPA, DHA or a combination thereof.
  • the provided composition according to the invention having a volume of 100 mL can comprise from 5 g to 50 g of MCTs.
  • the composition can comprise from 10 g to 50 g of MCTs, from 15 g to 50 g of MCTs, from 20 g to 50 g of MCTs, from 25 g to 50 g of MCTs, from 30 g to 50 g of MCTs, from 35 g to 50 g of MCTs, from 40 g to 50 g of MCTs, or from 45 g to 50 g of MCTs.
  • the composition can comprise from 5 g to 10 g of MCTs, from 5 g to 15 g of MCTs, from 5 g to 20 g of MCTs, from 5 g to 25 g of MCTs, from 5 g to 30 g of MCTs, from 5 g to 35 g of MCTs, from 5 g to 40 g of MCTs, or from 5 g to 45 g of MCTs.
  • Preference is given to a composition comprising from 10 g to 40 g of MCTs, for example from 15 g to 35 g.
  • the provided composition according to the invention having a volume of 100 mL can comprise 0.1 mg-0.5 mg of iron.
  • the composition can comprise 0.15 mg-0.5 mg of iron, 0.2 mg-0.5 mg of iron, 0.25 mg-0.5 mg of iron, 0.3 mg-0.5 mg of iron, 0.35 mg-0.5 mg of iron, 0.4 mg-0.5 mg of iron or 0.45 mg-0.5 mg of iron.
  • the composition can comprise 0.1 mg-0.45 mg of iron, 0.1 mg-0.4 mg of iron, 0.1 mg-0.35 mg of iron, 0.1 mg-0.3 mg of iron, 0.1 mg-0.25 mg of iron, 0.1 mg-0.2 mg of iron, 0.1 mg-0.15 mg of iron.
  • Preference is given to a composition comprising 0.15 mg-0.45 mg of iron, for example 0.2 mg-0.4 mg of iron.
  • a composition having a volume of 50 mL is disclosed, which differs from the above-disclosed solution having a volume of 100 mL in that it comprises only half the amount of each ingredient disclosed for the composition having the volume of 100 mL.
  • a method for administering the composition according to the invention is provided.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the method for administering a composition comprising omega-3 fatty acids selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a combination thereof, to a patient who has developed cancer, in order to improve the efficacy of a chemotherapy or of a radiation therapy and/or to prevent or reduce adverse effects caused by the chemotherapy or the radiation therapy, the method comprising the following steps: (a) the administration of the composition prior to the start of a cycle of the chemotherapy or of the radiation therapy, wherein the composition is administered from 96 hours to 24 hours prior to the start of a cycle of the chemotherapy or of the radiation therapy, preferably wherein the composition is administered from 72 to 24 hours prior to the start of a cycle of the chemotherapy or of the radiation therapy, very particularly preferably wherein the composition is administered from 48 to 24 hours prior to the start of a cycle of the chemotherapy or of the radiation therapy; (b) treatment of the patient with at least one cycle of a chemotherapy or radiation therapy.
  • omega-3 fatty acids selected from
  • step (a) can be carried out once or repeatedly, for example twice, three times, four times or five times.
  • step (b) the patient can be treated with, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 cycles of a chemotherapy or radiation therapy.
  • the method can further comprise the step: (a)′ additional administration of the composition is also additionally administered between 24 hours and 1 hour prior to the start of the cycle of the chemotherapy or radiation therapy, preferably wherein the composition is administered 3 hours prior to the start of a cycle of the chemotherapy or of the radiation therapy.
  • the administration in step (a)′ can be carried out once or repeatedly, for example twice, three times, four times or five times.
  • the method can be carried out such that from 5 mg to 250 mg of EPA per kilogram of body weight per day are administered, preferably wherein from 20 mg to 80 mg of EPA per kilogram of body weight per day are administered, most preferably wherein from 40 mg to 60 mg of EPA per kilogram of body weight per day are administered, and/or such that from 5 mg to 250 mg of DHA per kilogram of body weight per day are administered, preferably wherein from 20 mg to 80 mg of DHA per kilogram of body weight per day are administered, most preferably wherein from 40 mg to 60 mg of DHA per kilogram of body weight per day are administered.
  • Steps (a) and/or (a)′ of the method can be repeated, wherein the composition is preferably administered consecutively on multiple successive days, preferably wherein the composition is administered on three successive days.
  • composition can be administered parenterally, preferably intravenously.
  • the method can additionally comprise the step: (c) additional administration of the composition during or after a cycle of the chemotherapy or radiation therapy.
  • the method can be used to prevent or reduce adverse effects caused by the chemotherapy or the radiation therapy, wherein the adverse effects are preferably selected from the group consisting of gastrointestinal adverse effects, hematologic adverse effects, reduction in liver weight, neurotoxic adverse effects, adverse effects affecting the heart, inflammatory adverse effects, weight loss, limited function of the immune system, reduction of inflammations or a combination thereof.
  • the method can be used to treat cancers, wherein the cancer is selected from the group consisting of solid tumors and nonsolid tumors, preferably wherein the solid tumors are selected from the group consisting of colorectal cancer, breast cancer, pancreatic cancer, liver cancer, lung cancer, and stomach cancer.
  • the method can be used in patients receiving chemotherapy, preferably wherein the chemotherapy comprises a chemotherapeutic selected from the group consisting of 5-fluorouracil, gemcitabine, doxorubicin, paclitaxel, mitomycin, cyclophosphamide, epirubicin, arabinosylcytosine, tamoxifen, irinotecan, oxaliplatin, folinic acid, cisplatin, taxanes, vinca alkaloids, epipodophyllotoxins, synthetic alkaloids, cytarabine, nitrosourea, dacarbazine, fludarabine, ifosfamide, mitomycin C, tamoxifen or a combination thereof.
  • chemotherapeutic selected from the group consisting of 5-fluorouracil, gemcitabine, doxorubicin, paclitaxel, mitomycin, cyclophosphamide, epirubicin, arabinosylcytosine, t
  • the chemotherapy comprises 5-fluorouracil
  • very particular preference is given to the method in which the chemotherapy is FOLFOX or FOLFIRI.
  • the method can be used in patients receiving radiation therapy, preferably wherein the radiation therapy is selected from the group consisting of teletherapy and brachytherapy.
  • composition administered by means of the method can contain further preferred additives selected from the group consisting of medium-chain fatty acids and iron, or a combination thereof.
  • composition administered by means of the method can contain from 0.5 g/100 mL to 10.0 g/100 mL EPA and/or from 0.5 g/100 mL to 10.0 g/100 mL DHA, preferably from 0.7 g/100 mL to 3.5 g/100 mL EPA and/or from 0.7 g/100 mL to 3.5 g/100 mL DHA.
  • Very particular preference is given to the composition containing from 1 g/100 mL to 3.1 g/100 mL EPA and/or DHA.
  • Eicosapentaenoic acid 0.5 g-5 g or 2.5 g b
  • a composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • DHA Docosahexaenoic acid
  • Eicosapentaenoic acid 0.5 g-5 g or 2.5 g
  • DHA Docosahexaenoic acid
  • Sodium oleate, sodium hydroxide, and water for injection are used as excipients.
  • Composition Comprising Eicosapentaenoic Acid (EPA) and/or Docosahexaenoic Acid (DHA) with Admixtures (MCTs, Iron)
  • EPA Eicosapentaenoic Acid
  • DHA Docosahexaenoic Acid
  • MCTs, Iron Admixtures
  • Eicosapentaenoic acid 0.5 g-5 g or 2.5 g MCTs 5 g-50 g or 25 g b
  • a composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • DHA Docosahexaenoic acid 0.5 g-5 g or 2.5 g MCTs 5 g-50 g or 25 g c)
  • a composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • Eicosapentaenoic acid 0.5 g-5 g or 2.5 g
  • DHA Docosahexaenoic acid
  • a composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • Eicosapentaenoic acid 0.5 g-5 g or 2.5 g Iron 0.1 mg-5 mg or 2.5 mg e
  • a composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • DHA Docosahexaenoic acid 0.5 g-5 g or 2.5 g Iron 0.1 mg-5 mg or 2.5 mg f)
  • a composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • Eicosapentaenoic acid 0.5 g-5 g or 2.5 g
  • DHA Docosahexaenoic acid
  • Iron 0.1 mg-5 mg or 2.5 mg g A composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • Eicosapentaenoic acid 0.5 g-5 g or 2.5 g MCTs 5 g-50 g or 25 g Iron 0.1 mg-5 mg or 2.5 mg h
  • a composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • DHA Docosahexaenoic acid 0.5 g-5 g or 2.5 g MCTs 5 g-50 g or 25 g Iron 0.1 mg-5 mg or 2.5 mg i)
  • a composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • Eicosapentaenoic acid 0.5 g-5 g or 2.5 g
  • Docosahexaenoic acid 0.5 g-5 g or 2.5 g
  • MCTs 5 g-50 g or 25 g
  • Iron 0.1 mg-5 mg or 2.5 mg j A composition comprising the following constituents (values based on 100 mL, unless otherwise indicated) was prepared:
  • Sodium oleate, sodium hydroxide and water for injection are used as excipients.
  • Consecutive intravenous administration of Omegaven® was carried out two days and one day prior to the start of a cycle of a 5-FU-based adjuvant chemotherapy in a patient with colorectal cancer.
  • the chemotherapy regimen applied for the patient is the so-called FOLFOX regimen.
  • Omegaven® is administered in a dose of 2 mL per kg of patient body weight per day (see also FIGS. 1 and 3 ).
  • Omegaven® is, in each case, carried out prior to the start of a cycle of a chemotherapy comprising 12 cycles. Omegaven® is administered prior to each of the 12 cycles. Each cycle is followed by a multiday treatment break in which the patient does not receive any chemotherapeutics, and which lasts until the start of the next cycle of the chemotherapy. Omegaven® is, in each case, administered prior to the start of a cycle, i.e., during the treatment break.
  • Consecutive intravenous administration of Omegaven® is carried out two days, one day and on the day of the start of a cycle of a 5-FU-based adjuvant chemotherapy according to the FOLFOX regimen in a patient with colorectal cancer.
  • the administration on the day of the start of the chemotherapy cycle is carried out 3 hours prior to the start of the cycle, and is completed no later than one hour prior to the start of the cycle.
  • Omegaven® is administered in a dose of 2 mL per kg of patient body weight per day (see also FIG. 2 ).
  • the experiment uses female NMRI nu/nu mice (Elevage Janvier, Le Genest St Isle, France) aged between 7 and 8 weeks and weighing about 25 g. After receipt, the animals are injected with 2 ⁇ 10 6 cells/0.1 mL of the human colorectal-cancer cell line LS174T, and kept in isolator cages for two weeks under standardized, defined pathogen-free conditions; autoclaved litter and feed are used.
  • mice having tumors of about 30 mm 3 are divided up into the various experimental groups. The division is carried out such that comparable mean tumor volumes are present among the groups.
  • Animals of group A receive, 48 hours and 24 hours prior to the start of a treatment with 5-FU, an intravenous infusion with Omegaven® in each case (2 mL per kg of body weight per day; corresponding to 60 ⁇ L of Omegaven® per 200 ⁇ L of saline in the case of a weight of 30 g). The injection is carried out via the tail vein.
  • Animals of group B receive, in addition to the infusion with Omegaven® 48 hours and 24 hours, a further infusion with Omegaven® three hours prior to the start of the treatment with 5-FU.
  • Animals of control group C receive, 48 hours and 24 hours prior to the start of the treatment with 5-FU, an intravenous infusion with Lipovenös® in each case in an appropriate dose.
  • Animals of control group D receive, 24 hours and 48 hours after the start of the treatment with 5-FU, an intravenous infusion with Omegaven® in each case (2 mL per kg of body weight per day).
  • the treatment with 5-FU (50 mg per kg of body weight per day) is carried out by intraperitoneal injection on seven successive days.
  • Tumor growth is determined by the measurement of the three orthogonal tumor diameters using a caliper by means of the formula
  • Tumor volume 4 ⁇ /3 ⁇ (length/2 ⁇ width/2 ⁇ height/2)
  • the measurement is carried out every two days. Changes in tumor volume are calculated with reference to the initial tumor volume of an animal.
  • animals of groups A and B have a lower mean tumor volume compared to animals of groups C and D.
  • a trend toward a reduced tumor volume in the animals of group B compared to group A is observed.
  • the incorporation of [ 125 I] in various tissues is determined by investigating the distribution of the radioactivity after a two-day pretreatment with potassium iodide and perchlorate in drinking water (to inhibit the uptake of radioactive iodine into thymus and stomach) and a one-off intravenous injection with 250 KBq of [ 125 I]. 24 hours after the injection, the animals are killed by CO 2 inhalation and the radioactivity in the tumor and in the various organs (lungs, heart, liver, stomach, small intestine, large intestine, spleen, kidneys) is measured in a y counter (Cobra QC 5002, Packard, US). The organ weights are recorded.
  • liver weight PEG 2 activity in liver homogenates (Bicyclo-PEG2 Enzyme Immunoassay Kit; Cayman Chemical, Ann Arbor, Mich., USA), and the extent of changes in the intestinal tract of the animals (examination of crypt height and apoptotic figures in formalin-fixed, paraffin-embedded histological preparations following hemalaun and eosin staining), and changes in the blood count (determination of the cell counts of the individual cellular blood components on the Cell-Dyn 3500R).
  • the liver weight of the animals of groups A and B is higher than that of the animals of group C, and the animals have a lower relative content of PGE 2 .
  • fewer changes in crypt and cell structure of the normal mucous membrane of the intestine occur in animals of groups A and B.
  • the animals of groups A and B have a more favorable blood count which is closer to normal values.
  • HT-29 colorectal cancer cells (ATCC number HTB-38) were cultured in Dulbecco's Modified Eagle's Medium (DMEM, product number D 5030, Sigma Chemie AG, Buchs, Switzerland) supplemented with 10% heat-inactivated fetal calf serum (FBS), 1 g/L D-glucose, 3.7 g/L sodium bicarbonate and 0.1 g/L penicillin-streptomycin (all additives from Life Technologies Inc., Grand Island, N.Y.). The cells were cultured at 37° C. in a humidified atmosphere with a 5% CO 2 content and kept in the exponential growth phase by twice weekly subculturing. The cultures were tested for mycoplasma infection using the MycoAlert Detection Kit (product number LT07-118, Cambrex, Verviers, Belgium).
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS heat-inactivated fetal calf serum
  • the culture medium of the cells was replaced with medium which contained the relevant concentrations (0 ⁇ M, 20 ⁇ M, 50 ⁇ M or 100 ⁇ M) of DHA or EPA.
  • Controls were cultured in medium without EPA and without DHA.
  • the cells were cultured for 48 hours in the various media, and then irradiated with an individual radiation dose of 0 Gy (control), 2 Gy, 4 Gy or 6 Gy in an X-ray 6 MV instrument.
  • the cells were then detached from the culture vessel by means of trypsinization (lx trypsin-EDTA, Life Technologies Inc., Grand Island, N.Y.), resuspended and counted.
  • the cells were subsequently serially diluted according to a standard protocol and seeded in 100 ⁇ 20 mm cell culture dishes containing 10 mL of cell culture medium in a cell count which leads to the formation of about 200 colonies. After a 14-day incubation at 37° C., the vessels were washed with phosphate-buffered saline (PBS, Life Technologies Inc., Grand Island, N.Y.), fixed, and stained with a 0.5% crystal violet solution in methanol/glacial acetic acid (3:1, v/v). The surviving cell fraction was calculated with reference to the untreated controls (S/S0).
  • the results (see FIG. 4 ) of the experiment indicate a synergistic effect of a dose of from 20 ⁇ M to 100 ⁇ M of the omega-3 fatty acids DHA and EPA with irradiation of from 2 to 6 Gy (see FIG. 4 ).
  • HT-29 Human cancer cell lines (HT-29; ATCC number HTB-38) are cultured in Dulbecco's Modified Eagle's Medium (DMEM, product number D 5030, Sigma Chemie AG, Buchs, Switzerland) supplemented with 10% heat-inactivated fetal calf serum (FBS), 1 g/L D-glucose, 3.7 g/L sodium bicarbonate and 0.1 g/L penicillin-streptomycin (all additives from Life Technologies Inc., Grand Island, N.Y.). The cells are cultured at 37° C. in a humidified atmosphere with a 5% CO 2 content and kept in the exponential growth phase by twice weekly subculturing. The cultures are tested for mycoplasma infection using the MycoAlert Detection Kit (product number LT07-118, Cambrex, Verviers, Belgium).
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS heat-inactivated fetal calf serum
  • the cytotoxic effect of treatment of the cells with DHA, EPA, MCTs and iron on irradiation of the cells at 0 Gy, 2 Gy, 4 Gy or 6 Gy is examined in a 15-day clonogenicity experiment.
  • the culture medium of the cells is replaced with medium containing the relevant concentrations (0 ⁇ M, 20 ⁇ M, 50 ⁇ M or 100 ⁇ M) of DHA or EPA.
  • the cells are cultured for 48 hours in the medium, and then irradiated with an individual radiation dose of 0 Gy (control), 2 Gy, 4 Gy or 6 Gy in an X-ray 6 MV instrument.
  • a media change is carried out 48 hours prior to the irradiation; the cells receive normal culture medium. After 48 hours, the cells are irradiated with an individual radiation dose of 0 Gy (control), 2 Gy, 4 Gy or 6 Gy in an X-ray 6 MV instrument.
  • the cells are then detached from the culture vessel by means of trypsinization (lx trypsin-EDTA, Life Technologies Inc., Grand Island, N.Y.), resuspended and counted.
  • trypsinization lx trypsin-EDTA, Life Technologies Inc., Grand Island, N.Y.
  • the cells are subsequently serially diluted according to a standard protocol and seeded in 100 ⁇ 20 mm cell culture dishes containing 10 mL of medium in a cell count which leads to the formation of about 200 colonies.
  • Cells of groups A and C are seeded in normal culture medium, and cells of group B are seeded in medium containing the relevant concentrations (0 ⁇ M, 20 ⁇ M, 50 ⁇ M or 100 ⁇ M) of DHA or EPA.
  • the vessels are washed with phosphate-buffered saline (PBS, Life Technologies Inc., Grand Island, N.Y.), fixed, and stained with a 0.5% crystal violet solution in methanol/glacial acetic acid (3:1, v/v). The surviving cell fraction is calculated with reference to the untreated controls (S/S0).
  • PBS phosphate-buffered saline
  • tumor cell lines colonal cancer cell lines, breast cancer cell lines and lung cancer cell lines.
  • EPA or DHA cytotoxic effect of pretreatment with EPA or DHA compared to post treatment with EPA or DHA.
  • mice After the inoculation with tumor cells and the growth of the tumors, the mice are divided up into the various experimental groups. The division is carried out such that comparable mean tumor volumes are present among the groups.
  • Group A receives, 48 and 24 prior to the start of the irradiation, an intravenous infusion with Omegaven® in each case (2 mL per kg of body weight per day; corresponding to 60 ⁇ L of Omegaven® per 200 ⁇ L of saline in the case of a weight of 30 g). The injection is carried out via the tail vein. Animals of group B receive, in addition to the infusion with Omegaven® 48 hours and 24 hours, a further infusion with Omegaven® three hours prior to the start of the irradiation.
  • Animals of control group C receive, 48 hours and 24 hours prior to the start of the irradiation, an intravenous infusion with Lipovenös® in each case in an appropriate dose.
  • Animals of control group D receive, 24 hours and 48 hours after the start of the irradiation, an intravenous infusion with Omegaven® in each case (2 mL per kg of body weight per day).
  • the irradiation of the tumors is carried out by two-time irradiation at 7.5 Gy.
  • Tumor growth is determined by the measurement of the three orthogonal tumor diameters using a caliper by means of the formula
  • Tumor volume 4 ⁇ /3 ⁇ (length/2 ⁇ width/2 ⁇ height/2)
  • the measurement is carried out every two days. Changes in tumor volume are calculated with reference to the initial tumor volume of an animal.
  • animals of groups A and B have a lower mean tumor volume compared to animals of groups C and D.
  • a trend toward a reduced tumor volume in the animals of group B compared to group A is observed.
  • the female C57 black mice used are kept as described above.
  • the animals of group A receive, 48 and 24 prior to the start of the irradiation, an intravenous infusion with Omegaven® in each case (2 mL per kg of body weight per day; corresponding to 60 ⁇ L of Omegaven® per 200 ⁇ L of saline in the case of a weight of 30 g).
  • the injection is carried out via the tail vein.
  • Animals of group B receive, in addition to the infusion with Omegaven® 48 hours and 24 hours, a further infusion with Omegaven® three hours prior to the start of the irradiation.
  • Animals of control group C receive, 48 hours and 24 hours prior to the start of the irradiation, an intravenous infusion with Lipovenös® in each case in an appropriate dose.
  • Animals of control group D receive, 24 hours and 48 hours after the start of the irradiation, an intravenous infusion with Omegaven® in each case (2 mL per kg of body weight per day).
  • the irradiation of the animals is carried out at an individual dose of 16.5 Gy.
  • the animals are shielded by lead plates such that the snout of the animals is selectively irradiated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US13/819,952 2010-09-03 2011-08-26 Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy Abandoned US20130197087A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/819,952 US20130197087A1 (en) 2010-09-03 2011-08-26 Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37977510P 2010-09-03 2010-09-03
EP101752939 2010-09-03
EP10175293A EP2425833A1 (de) 2010-09-03 2010-09-03 Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
US13/819,952 US20130197087A1 (en) 2010-09-03 2011-08-26 Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy
PCT/EP2011/064693 WO2012028543A1 (de) 2010-09-03 2011-08-26 Zusammensetzung umfassend eine kombination von dha und epa zur gabe vor beginn der chemotherapie

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/064693 A-371-Of-International WO2012028543A1 (de) 2010-09-03 2011-08-26 Zusammensetzung umfassend eine kombination von dha und epa zur gabe vor beginn der chemotherapie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/674,747 Continuation US9675574B2 (en) 2010-09-03 2015-03-31 Composition comprising a combination of DHA and EPA for administration prior to commencement of chemotherapy

Publications (1)

Publication Number Publication Date
US20130197087A1 true US20130197087A1 (en) 2013-08-01

Family

ID=43244801

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/819,952 Abandoned US20130197087A1 (en) 2010-09-03 2011-08-26 Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy
US14/674,747 Active US9675574B2 (en) 2010-09-03 2015-03-31 Composition comprising a combination of DHA and EPA for administration prior to commencement of chemotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/674,747 Active US9675574B2 (en) 2010-09-03 2015-03-31 Composition comprising a combination of DHA and EPA for administration prior to commencement of chemotherapy

Country Status (12)

Country Link
US (2) US20130197087A1 (de)
EP (2) EP2425833A1 (de)
CN (1) CN103200939A (de)
DK (1) DK2611439T3 (de)
ES (1) ES2664568T3 (de)
HR (1) HRP20180787T1 (de)
LT (1) LT2611439T (de)
NO (1) NO2611439T3 (de)
PL (1) PL2611439T3 (de)
PT (1) PT2611439T (de)
TR (1) TR201807070T4 (de)
WO (1) WO2012028543A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011623A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
CN111714616A (zh) * 2019-07-17 2020-09-29 江苏西宏生物医药有限公司 一种用于抗肿瘤的组合物
US11261151B2 (en) 2017-09-11 2022-03-01 Atossa Therapeutics, Inc. Methods for making and using endoxifen

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540292A1 (de) * 2011-06-28 2013-01-02 Nestec S.A. DHA und EPA zur Reduktion oxidativer Belastung
CN106390122A (zh) * 2015-07-31 2017-02-15 舟山三合生物科技有限公司 化疗类抗癌药口服制剂组合物
US11406614B2 (en) 2016-10-11 2022-08-09 Fresenius Kabi Deutschland Gmbh Composition comprising EPA and DHA for an enhanced efficacy of anticancer agents
CN106995448B (zh) * 2017-04-17 2019-04-30 西安医学院 一种dha-丝裂霉素c衍生物及其制备方法和应用
WO2018208593A1 (en) 2017-05-09 2018-11-15 Baxter International Inc. Parenteral nutrition diagnostic system, apparatus, and method
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
CN115845056A (zh) * 2022-07-22 2023-03-28 山东大学齐鲁医院 DHA通过抑制心肌细胞中p38/ET-1通路在防治放射性心肌纤维化中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8642077B2 (en) * 2009-04-29 2014-02-04 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
US6949064B2 (en) * 2000-10-20 2005-09-27 Bard Brachytherapy, Inc. Brachytherapy seed deployment system
US20030068385A1 (en) * 2001-03-23 2003-04-10 Moyer Mary Pat Accelerated action fatty acid (AAFA) promotes health of normal tissues and minimizes the toxic side effects of chemotherapy
DE10224171A1 (de) 2002-05-31 2003-12-18 Fresenius Kabi Austria Gmbh Gr Pharmazeutische Zusammensetzung, die Arsentrioxid und mindestens eine langkettige, mehrfach ungesättigte Fettsäure umfaßt
US9034389B2 (en) * 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US8642077B2 (en) * 2009-04-29 2014-02-04 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011623A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
US11261151B2 (en) 2017-09-11 2022-03-01 Atossa Therapeutics, Inc. Methods for making and using endoxifen
US11572334B2 (en) 2017-09-11 2023-02-07 Atossa Therapeutics, Inc. Methods for making and using endoxifen
US11680036B1 (en) 2017-09-11 2023-06-20 Atossa Therapeutics, Inc. Methods for making and using endoxifen
CN111714616A (zh) * 2019-07-17 2020-09-29 江苏西宏生物医药有限公司 一种用于抗肿瘤的组合物

Also Published As

Publication number Publication date
PT2611439T (pt) 2018-04-17
DK2611439T3 (en) 2018-06-06
CN103200939A (zh) 2013-07-10
WO2012028543A1 (de) 2012-03-08
HRP20180787T1 (hr) 2018-06-29
LT2611439T (lt) 2018-06-25
EP2611439A1 (de) 2013-07-10
EP2611439B1 (de) 2018-02-21
ES2664568T3 (es) 2018-04-20
TR201807070T4 (tr) 2018-06-21
PL2611439T3 (pl) 2018-09-28
US9675574B2 (en) 2017-06-13
NO2611439T3 (de) 2018-07-21
EP2425833A1 (de) 2012-03-07
US20150297549A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
US9675574B2 (en) Composition comprising a combination of DHA and EPA for administration prior to commencement of chemotherapy
Douple et al. Carboplatin as a potentiator of radiation therapy
JP5920902B2 (ja) 放射線障害の予防及び／又は治療剤
BR112012029170B1 (pt) uso de um fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo
JP6051283B2 (ja) 抗ガン剤の副作用の予防剤及び／又は治療剤
JP5818905B2 (ja) エリスロポエチン産生促進剤
CN108503676B (zh) 用于癌症治疗的果糖类似物及其组合物
JPWO2013054770A1 (ja) がん性貧血改善・予防剤
WO2020179125A1 (ja) 放射線増感剤
TWI827383B (zh) 普魯士藍金屬錯合物之奈米框架之製備方法以及其用於治療癌症的方法
RU2713725C1 (ru) Биологически активная добавка и способ ее применения
US20240180830A1 (en) Methods for treating cancers by using nanoframes of prussian blue or an analogue thereof and its production methods
CN117860899A (zh) 化合物或其药学上可接受的盐制备用于治疗癌症的药物组合物的用途
Konno et al. Increased lethality and delay in the recovery of hemopoietic stem cells after irradiation in mice exposed to nitrous oxide
Hossain et al. Comparative study of efficacy of oral iron versus parenteral iron in the treatment of iron deficiency anaemia
JP2020143040A (ja) 放射線増感剤
JP2022140615A (ja) プラズマ療法によるがんまたは腫瘍の治療効果を増強
JP2023511072A (ja) 癌の治療のための組み合わせおよびその用途
JP2015091766A (ja) 癌治療支援システム
CN110876803A (zh) 一种包含乳蛋白和油酸的药物组合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: FRESENIUS KABI DEUTSCHLAND GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHLOTZER, EWALD;KRAMPITZ, BARBARA;SUCHNER, ULRICH;SIGNING DATES FROM 20130304 TO 20130325;REEL/FRAME:030105/0794

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION